VXRT Jan 2025 0.500 put
| Previous close | 0.1500 |
| Open | 0.1500 |
| Bid | 0.0500 |
| Ask | 0.2500 |
| Strike | 0.50 |
| Expiry date | 2025-01-17 |
| Day's range | 0.1500 - 0.1500 |
| Contract range | N/A |
| Volume | |
| Open interest | 245 |
Simply Wall St.While institutions invested in Vaxart, Inc. (NASDAQ:VXRT) benefited from last week's 23% gain, retail investors stood to gain the most
Key Insights Significant control over Vaxart by retail investors implies that the general public has more power to...
GlobeNewswireVaxart Provides Business Update
— Cash runway extended into 2026 — — Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 million — — Company well-capitalized to execute on multiple key clinical and regulatory milestones in COVID-19 and norovirus programs — SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today provided business and cash runway updates as the Company continues to advance its oral pill vaccine platform. Vaxart anticipates that net proceeds
- GlobeNewswire
Vaxart Announces $40 Million Underwritten Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart”) (Nasdaq: VXRT) today announced an underwritten offering of 50,000,000 shares of its common stock at an offering price of $0.80 per share, which is a premium to the last closing price of $0.75 per share. Gross proceeds to Vaxart from the offering are expected to be $40 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Vaxart. The offering is expected to
